Biosimilar for Crohn's Noninferior to Adalimumab Biosimilar for Crohn's Noninferior to Adalimumab

A patent dispute means that the marketing of a biosimilar for patients with inflammatory bowel disease will be delayed, despite approval by the US Food and Drug Administration, investigators report.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Related Links:

CONCLUSIONS: Testing for S100B and calprotectin could be a useful screening tool to better predict IBD activity. PMID: 31957846 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Publication date: Available online 20 January 2020Source: Journal of the Formosan Medical AssociationAuthor(s): Shan-Han Chang, Hsin-Yun Sun, Chia-Tung Shun, Shu-Chen Wei
Source: Journal of the Formosan Medical Association - Category: General Medicine Source Type: research
Condition:   Crohn Disease Interventions:   Dietary Supplement: Modulen;   Drug: Budesonide Sponsor:   Hillel Yaffe Medical Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Crohn's Disease Intervention:   Drug: Mirikizumab Sponsor:   Eli Lilly and Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Crohn Disease Intervention:   Other: No intervention Sponsor:   Janssen-Cilag Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Crohn's Disease Intervention:   Drug: Mirikizumab Sponsor:   Eli Lilly and Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Crohn Disease Intervention:   Other: No intervention Sponsor:   Janssen-Cilag Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusion: MRE discloses disease activity and complications not apparent with other modalities and results in changes in therapeutic decisions. In addition to being used for diagnosis, MRE should be routinely used in the follow-up of CD patients. PMID: 31933630 [PubMed]
Source: Gastroenterology Research and Practice - Category: Gastroenterology Tags: Gastroenterol Res Pract Source Type: research
This review explores the role of gut fungi in patients with Crohn's disease and ulcerative colitis. Might modulation of the fungal microbiota present a therapeutic opportunity for IBD?Alimentary Pharmacology &Therapeutics
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Conclusions: Over the course of an extended follow-up period, there appeared to be changes in both disease location and behaviour in PCD. Interestingly, a significant proportion of patients had disease involution which may be related to a high rate of exposure to thiopurines and biologics. We were unable to identify any variables associated with complicated disease course or the need for intestinal surgery. PMID: 31928099 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Gastroenterology - Category: Gastroenterology Tags: Scand J Gastroenterol Source Type: research
More News: Crohn's Disease | Food and Drug Administration (FDA) | Gastroenterology | Health | Humira | Inflammatory Bowel Disease | Marketing